Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00386347 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
A Phase 1 study of HIV Infection and Infection, Human Immunodeficiency Virus, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT00386347 is a Phase 1 study of HIV Infection and Infection, Human Immunodeficiency Virus that has completed, run by GlaxoSmithKline. The registered enrollment target is 56 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00386347, a Phase 1 study of HIV Infection and Infection, Human Immunodeficiency Virus, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a two-part study. Part one is designed to see how different formulations of GSK364735 are absorbed in the body and To see how food affects how GSK364735 is absorbed in the body. Part two is designed to see how repeat dosing affects how GSK364735 is absorbed in the body.
Conditions Studied
Interventions
- DRUG GSK364735 oral solution and oral tablets
Study Locations (1)
Indiana
- GSK Investigational Site - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00386347
The ClinicalTrials.gov registry entry for NCT00386347 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (77% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which GSK364735 oral solution and oral tablets is the first listed.
NCT00386347 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00386347 about?
NCT00386347 is a clinical study titled "A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.". This study is a two-part study. Part one is designed to see how different formulations of GSK364735 are absorbed in the body and To see how food affects how GSK364735 is absorbed in the body. Part two is designed to see how repeat dosing affects how GSK364735 is absorbed in the body.
What is the current status of trial NCT00386347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2006-10.
What conditions does trial NCT00386347 study?
This clinical trial studies the following conditions: HIV Infection, Infection, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT00386347?
The interventions under investigation include: GSK364735 oral solution and oral tablets (DRUG).
Who is sponsoring clinical trial NCT00386347?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00386347 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
RECRUITING · Phase 1
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.